Novo Nordisk (NOVOB DC), at its shareholder meeting, said pricing headwinds are the primary near-term drag, ex-US semaglutide loss-of-exclusivity is also putting downward pressure on prices with the net effect of volume growth but revenue compression

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

US EIA Natural Gas Stocks Change (Mar/20) -54

6.2 magnitude earthquake reported off the coast of Honshu, Japan by GFZ

Novo Nordisk (NOVOB DC), at its shareholder meeting, said pricing headwinds are the primary near-term drag, ex-US semaglutide loss-of-exclusivity is also putting downward pressure on prices with the net effect of volume growth but revenue compression

Brazilian President Lula says that currently China is the best partner of Brazil

US Treasury has removed sanctions on a number of Belarussian entities

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Novo Nordisk's announcement highlights significant pricing pressures on its products, particularly due to loss of exclusivity for semaglutide in markets outside the U.S. This suggests potential underperformance in revenue growth despite volume increases, which could influence market sentiment and weigh on the stock, especially amid broader sector dynamics.

Related headlines

The feed had this first.

Use the Platform